Search
Now showing items 21-30 of 41
Identifying effective characteristics of behavioral weight management interventions for people with serious mental illness: A systematic review with a qualitative comparative analysis
(2021-10)
People with serious mental illness (SMI) have identified barriers to engaging in behavioral weight management interventions (BWMIs). We assessed whether BWMIs that addressed these barriers were more effective. First, we ...
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
(2021-12)
The cognitive dysfunction experienced by patients with schizophrenia represents a major unmet clinical need. We believe that enhancing synaptic function and plasticity by targeting kalirin may provide a novel means to ...
The service user experience of SlowMo therapy: A co-produced thematic analysis of service users' subjective experience
(2022-04)
Objectives: SlowMo is the first blended digital therapy for paranoia, showing significant small-moderate reductions in paranoia in a recent large-scale randomized controlled trial (RCT). This study explored the subjective ...
Body image concerns in patients with persecutory delusions
(2022-04)
Background: Persecutory fears build on feelings of vulnerability that arise from negative views of the self. Body image concerns have the potential to be a powerful driver of feelings of vulnerability. Body image concerns ...
Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14–18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS)
(2019-07)
Background: Adolescent-onset psychosis is associated with more severe symptoms and poorer outcomes than adult-onset psychosis. The National Institute for Clinical Excellence (NICE) recommend that adolescents with first ...
Association of Schizophrenia Spectrum Disorders and Violence Perpetration in Adults and Adolescents From 15 Countries A Systematic Review and Meta-analysis
(2021-12)
Violence perpetration outcomes in individuals with schizophrenia spectrum disorders contribute to morbidity and mortality at a population level, disrupt care, and lead to stigma.
Objective : To conduct a systematic ...
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
(2022-02)
IMPORTANCE Most evidence about efficacy and safety of antipsychotics in schizophrenia
spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict
eligibility criteria, RCTs represent ...
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)
After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ...
A life more ordinary: A peer research method qualitative study of the Feeling Safe Programme for persecutory delusions
(2022-07)
Background: The Feeling Safe Programme is a cognitive
therapy developed to improve outcomes for individuals with
persecutory delusions. It is theoretically driven, modular
and personalised, with differences in ...
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
(2023-06)
Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate ...